Meyka AI API is live for developers.Start building.
Advertisement
Genmab A/S

Genmab A/S (GMAB) Stock Overview

Explore Genmab A/S’s financial performance, market position, analyst ratings, and future outlook.

GMABā—NASDAQ
HealthcareBiotechnology
$25.15
$0.42(1.70%)
U.S. Market opens in 45h 14m
Advertisement

Genmab A/S (GMAB)

Meyka AI Score

Z

Key Financials

Market Cap15.4B
P/E Ratio18.71
EPS (TTM)$1.32
ROE0.15%
Fundamental Analysis

AI Price Forecasts

1 Month$29.18
3 Months$29.63
1 Year Target$34.68

GMAB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Genmab A/S (GMAB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 43.01, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $34.68.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 18.71 and a market capitalization of 15.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.70%
5-Day Change
-6.68%
1-Month Change
-8.61%
3-Month Change
-8.48%
6-Month Change
-20.76%
Year-to-Date (YTD) Change
-18.34%
1-Year Change
15.31%
3-Year Change
-35.78%
5-Year Change
-39.18%
All-Time (Max) Change
567.11%

Contact Information

45 70 20 27 28
Kalvebod Brygge 43, Copenhagen, NaN, 1560

Company Facts

2,638 Employees
IPO DateJun 1, 2009
CountryDK
Actively Trading

Frequently Asked Questions